Terbutaline modified-release - Vectura

Drug Profile

Terbutaline modified-release - Vectura

Alternative Names: SKP-1052

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SkyePharma PLC
  • Developer Vectura
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Small molecules; Tocolytics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hypoglycaemia

Highest Development Phases

  • Phase I Hypoglycaemia

Most Recent Events

  • 08 Sep 2016 Terbutaline modified-release is still in phase I development for Hypoglycaemia (Prevention) (Skyepharma Pipeline, September 2016)
  • 02 Sep 2011 Terbutaline modified-release - Skye Pharma is available for licensing as of 02 Sep 2011.
  • 22 Feb 2011 Phase-I clinical trials in Hypoglycaemia (prevention) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top